VC: Cerimon Pharmaceuticals leads with $70M first round
Cerimon Pharmaceuticals leads with $70M first round.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Creimon
|
$70M
|
MPM Capital |
The money will be used to expand its product pipeline through innovative partnering transactions and product acquisitions. |
|
Devax
|
$32M
|
InterWest Partners, U.S. Venture Partners |
The funding will be used to finance its US IDE clinical study and international marketing of the Axxess drug eluting bifurcation stent. |
|
Surface Logix
|
$32M
|
Venrock Associates |
Surface Logix will use the funds to continue the development of SLx-2101, a potent, long acting PDE5 inhibitor, and to bring new proprietary programs into the clinic. |
|
Marinus Pharmaceuticals
|
$29.4M
|
Domain Associates, Sofinnova Ventures, Canaan Partners |
The funds will be used primarily for the in-licensing and development of clinical stage drugs to treat neurological, psychiatric and pain disorders. |
|
TransOral Pharmaceuticals
|
$23M
|
Partners |
The money will go to development of their lead products, which will compete in the sleep and migraine therapeutic markets. |
|
Celleration
|
$20.6M
|
Triathalon Medical Ventures |
Celleration is developing MIST Therapy in patients with chronic and hard to heal wounds. |
|
ForteBio
|
$17.3M
|
Vertical |
The money will assemble a marketing and sales organization in preparation for the launch of ForteBio's first product. |
|
Viral Therapies
|
$8M
|
MedVenture Associates |
The proceeds will initiate further clinical studies of the Extracorporeal Liver Assist Device system. |
|
Molecular Profiling Institute
|
$7.5M
|
AmeriPath, Affymetrix, Gen-Probe |
The funding will help launch additional molecular tests for breast cancer, prostate cancer, and lymphoma. |
Comments